Valor nutricional do mel e pólen de abelhas sem ferrão da região Amazônica

Avaliou-se os constituintes nutricionais de amostras do mel e pólen das espécies Melipona seminigra merrillae (jandaíra), Melipona compressipes manaosensis (jupará), Melipona rufiventris paraensis (uruçu boca de ralo), provenientes do meliponário da Fazenda Poranga no município de Itacoatiara - AM e Meliponário Abelhudo em Manaus - AM. Os resultados demonstraram o potencial do mel como fonte de energia, particularmente a M. rufiventris com 305,3±2,4 kcal em 100g. O pólen da espécie M. compressipes apresentou a maior concentração de proteína 15,7±0,0% e energia 309,8±0,8 kcal. Tais constatações sugerem a implementação de novos estudos visando à incorporação destes produtos na dieta dos amazônidas, possibilitando uma nova fonte alternativa de alimento potencialmente nutritivo e saudável.<br>We evaluated the nutricional constituent of honey and pollen samples of the Melipona species seminigra merrillae (jandaíra) Melipona compressipes manaosensis (jupará), Melipona rufiventris paraensis (uruçu boca de ralo), proceeding from the Poranga Honey Farm in Itacoatiara - AM, and Meliponário Abelhudo in Manaus, AM. The results demonstrated the potencial of honey as a source of energy, particularly the kcal M. rufiventris with 305.3±2.4 kcal in 100g. The compressis pollen of species presented the highest concentration of protein 15.7±0.0 % and energy 309.8±0.8 kcal. Thus we suggest the implementation of new studies aiming at the incorporation of these products in the diet of the Amazon population, making possible a new potentially nutritional and alternative healthful food source

Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study

Objectives To characterise peripheral musculoskeletal involvement in patients with spondyloarthritis (SpA) including psoriatic arthritis (PsA), across the world. Methods Cross-sectional study with 24 participating countries. Patients with a diagnosis of axial SpA (axSpA), peripheral SpA (pSpA) or PsA according to their rheumatologist were included. The investigators were asked which diagnosis out of a list of six (axSpA, PsA, pSpA, inflammatory bowel disease-associated SpA, reactive arthritis or juvenile SpA (Juv-SpA)) fitted the patient best. Peripheral manifestations (ie, peripheral joint disease, enthesitis, dactylitis and root joint disease), their localisation and treatments were evaluated. Results A total of 4465 patients were included (61% men, mean age 44.5 years) from four geographic areas: Latin America (n=538), Europe plus North America (n=1677), Asia (n=975) and the Middle East plus North Africa (n=1275). Of those, 78% had ever suffered from at least one peripheral musculoskeletal manifestation; 57% had peripheral joint disease, 44% had enthesitis and 15% had dactylitis. Latin American had far more often peripheral joint disease (80%) than patients from other areas. Patients with PsA had predominantly upper limb and small joint involvement (52%). Hip and shoulder involvement was found in 34% of patients. The prevalence of enthesitis ranged between 41% in patients with axSpA and 65% in patients with Juv-SpA. Dactylitis was most frequent among patients with PsA (37%). Conclusion These results suggest that all peripheral features can be found in all subtypes of SpA, and that differences are quantitative rather than qualitative. In a high proportion of patients, axial and peripheral manifestations coincided. These findings reconfirm SpA clinical subtypes are descendants of the same underlying disease, called SpA.Pathophysiology and treatment of rheumatic disease